Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications
Hematological Oncology · 2024
DOI: 10.1002/hon.3311 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hematological Oncology, 2024. Verfasst von N Polverelli und 22 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili, Brescia, Italy. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lombardy represents the largest region of Italy by population, with almost 10 million residents, a dimension similar to a medium size country like Sweden or Belgium. The CML subcommittee of the Lombardy Hematology Network (REL‐CML) conducted a study at the beginning of 2023. Prevalence was calculated by direct input from the 21 centers participating in REL‐CML. Tyrosine Kinase Inhibitors (TKI) prescription records collected from the ARIA regional registry were used to estimate the number of CML patients followed in smaller centers not participating in REL‐CML. A total of 2285 patients were registered, representing a prevalence of 0.23 ‰. These data were compared to a similar census conducted in 2005, at the beginning of the TKI era, where a prevalence of 0.029‰ was calculated. This indicates that an almost 10 times increase took place during this period of time. Imatinib represents the most frequently prescribed first‐line TKI; its use in 2022 still represented 75% of total first line prescriptions. An increased concentration of the care of CML patients in specialized REL centers with a decreased dispersion of patients in small centers was also evident over this 18 year period of time. Nineteen % of patients discontinued treatment, highlighting persisting logistical and biological challenges; one some recommendations on CML management are included to this aim.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili, Brescia, Italy.
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Oncology Department, ASST Lecco, Lecco, Italy.
- Unit of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy.
- Unit of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
- Hematology Unit, ASST Spedali Civili, Brescia, Italy.
ORCID-Profile: N Polverelli, A Iurlo, C Gambacorti-Passerini
Zitieren
APA
Polverelli, N., Anghilieri, M., Elena, C., Intermesoli, T., Pungolino, E., D'Adda, M., Iurlo, A., Maffioli, M., Lunghi, F., Bertolli, V., Orofino, N., Sissa, C., Fiamenghi, C., Gardellini, A., Ubezio, M., Carraro, M. C., Corradini, P., Giglio, F., Pasquini, M. C., …, & Gambacorti-Passerini, C. (2024). Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications. Hematological Oncology. https://doi.org/10.1002/hon.3311
Vancouver
Polverelli N, Anghilieri M, Elena C, Intermesoli T, Pungolino E, D'Adda M, et al. Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications. Hematological Oncology. 2024. doi:10.1002/hon.3311
BibTeX
@article{Polverelli2024,
author = {Polverelli, N and Anghilieri, M and Elena, C and Intermesoli, T and Pungolino, E and D'Adda, M and Iurlo, A and Maffioli, M and Lunghi, F and Bertolli, V and Orofino, N and Sissa, C and Fiamenghi, C and Gardellini, A and Ubezio, M and Carraro, M C and Corradini, P and Giglio, F and Pasquini, M C and Palazzolo, R and Calori, R and Ercolanoni, M and Gambacorti-Passerini, C},
title = {Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications},
journal = {Hematological Oncology},
year = {2024},
doi = {10.1002/hon.3311}
}
EUVIMED